Jincheng Pharm Releases Q3 2023 Financial Report and Obtains New License

Business by 2FIRSTS.ai
Oct.25.2023
Jincheng Pharm Releases Q3 2023 Financial Report and Obtains New License
Jincheng Pharm's Q3 financial report reveals a 16.77% YoY increase in revenue but a 21.95% decrease in net profit.

On October 24th, the listed company Jincheng Pharm (SZ300233) released its financial report for the third quarter of 2023. The company's operating income for the third quarter reached 863 million yuan, representing a year-on-year increase of 16.77%. However, its net profit declined by 21.95% to 30.77 million yuan, and the non-GAAP net profit also dropped by 21.17% to 26.72 million yuan.

Jincheng Pharm Releases Q3 2023 Financial Report and Obtains New License
Announcement|Source: Jincheng Pharm

 

According to a report, Jincheng Pharm achieved a total operating revenue of 2.569 billion yuan in the first three quarters of 2023, representing a year-on-year decrease of 0.87%. The net profit reached 132 million yuan, experiencing a significant decline of 48.73% compared to the same period last year. The adjusted net profit, excluding non-recurring items, stood at 119 million yuan, reflecting a 52.81% year-on-year decrease. The basic earnings per share amounted to 0.34 yuan.

 

According to the report, Jincheng Pharm Chemical Co., Ltd., a wholly-owned subsidiary of the company, received a "Tobacco Monopoly Production Enterprise License" (e-cigarette nicotine production) issued by the National Tobacco Monopoly Administration in July 2023.

 

It has been stated that the newly acquired "Tobacco Monopoly Production Enterprise License" has made changes to the approved production scale, scope of permission, and validity period of the original certificate. The company is now permitted to engage in domestic and export business of e-cigarette nicotine in compliance with the law. The production scale will not exceed the data approved by the State Tobacco Monopoly Bureau, and the validity period has been extended until June 30, 2025.

 

Disclaimer: 
This article is translated from an original Chinese article available on 2firsts.cn by AI, and has been reviewed and edited by 2FIRSTS's English editorial team. The Chinese original text is the only authoritative source of information. The exclusive copyright and license rights to this article are held by 2FIRSTS Technology Co., Ltd. Any reproduction, reprinting, or redistribution of this article, either in part or in full, requires express written permission from 2FIRSTS and must include clear attribution along with a link to this content. Non-compliance may result in legal action. 2FIRSTS Technology Co., Ltd. reserves the right to pursue legal actions in case of unauthorized use or distribution.